Cipla Ltd Share Price (CIPLA)
₹1375.2
Cipla Ltd share Performance
- ₹1371.55₹1391.95₹1375.2
0.27%
Low
Day's Volatility:1.48%
High
1.22%
- ₹896.3₹1519₹1375.2
34.82%
Low
52 Weeks Volatility:45.28%
High
10.46%
| Returns % | |
| 1 Month Return | -7.61 % |
| 3 Month Return | 6.28 % |
| 1 Year Return | 51.71 % |
| Market Stats | |
| Previous Close | ₹1,381.40 |
| Open | ₹1,385.00 |
| Volume | 14.34L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,11,029.12Cr |
Analyst Rating for Cipla Ltd stock
based on 35 analysts
Based on 35 analysts offering long term price targets for Cipla Ltd. An average target of ₹1449.31
Source: S&P Global Market Intelligence
Company Information
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Share Price: ₹1375.20 per share as on 17 Apr, 2024 02:04 AM
Market Capitalisation: ₹1,11,029.12Cr as of today
Revenue: ₹6,505.66Cr as on December 2023 (Q4 23)
Net Profit: ₹1,068.51Cr as on December 2023 (Q4 23)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Cipla Ltd
Cipla Acquires Cosmetics Business, ICICI Sets Target Price - 17 Apr, 2024
Cipla acquires Ivia Beaute's cosmetics and personal care distribution business for Rs 130 crore. ICICI Securities sets a buy call on Cipla with a target price of Rs 1,660 per share.
Cipla Acquires Cosmetics Business of Ivia Beaute - 16 Apr, 2024
Cipla Health Limited has signed a business transfer agreement to purchase the distribution and marketing business undertaking of Ivia Beaute Private's cosmetics and personal care business, which includes brands like Astaberry, Ikin, and Bhimsaini on a worldwide basis. The acquisition cost is set at ₹130 crore.
Cipla's Subsidiary Acquires Cosmetics Business; Technical Analysis Suggests Weakness - 15 Apr, 2024
Cipla Health Limited, a subsidiary of Cipla, has acquired the distribution and marketing business of Ivia Beaute Private Ltd for Rs 130 crore. However, technical analysis suggests further weakness in Cipla stock due to a confirmed Double Top pattern and negative divergence observed in RSI.
Cipla Ltd's Ownership Structure Analyzed by Experts - 12 Apr, 2024
Experts analyze Cipla Ltd's ownership structure, with institutions holding a 39% stake and insiders owning a reasonable proportion. Deven Choksey believes that Cipla offers clarity from the point of view of complex genetics and growth.
Cipla Receives Six Observations from USFDA - 10 Apr, 2024
The USFDA issued six observations for Cipla's Patalganga unit following a cGMP inspection. The company stated that it will work closely with the FDA to address these concerns within the stipulated timeframe. Cipla shares ended 1% lower at ₹1,449 and have declined in five out of the last six trading sessions.
Sanofi Forms Strategic Alliances with Cipla and Other Indian Pharma Firms - 07 Apr, 2024
Sanofi has partnered with prominent Indian pharmaceutical companies, including Cipla, to expand the market penetration of its products in India. The collaborations aim to maximize the impact of existing products and extend their reach across the country.
Cipla Board Likely to Announce Dividend, Goa Plant Under Observation - 06 Apr, 2024
Cipla is expected to declare a final dividend for FY 2023-24 on May 10th. The company reported a consolidated net profit of Rs 1,068.4 crore in the quarter ending December 2023. Meanwhile, Cipla's Goa plant is being observed, but its revenue growth has matched that of the sector.
Cipla Receives Observations from USFDA for Maharashtra Facility - 05 Apr, 2024
The US FDA has issued Form 483 with six observations after inspecting Cipla's Patalganga manufacturing facility in Maharashtra. Meanwhile, Cipla reported strong financial results for Q3 FY24, with a significant increase in consolidated net profit and revenue from operations.
Cipla's Profit Set to Increase Due to Robust Growth in Respiratory Portfolio - 03 Apr, 2024
Brokerage firm Sharekhan has highlighted a Buy call for Cipla, citing the company's strategic focus on complex respiratory products and resulting impact on margins. The report also predicts an upward trajectory for the company's profit.
Cipla Partners with Sanofi India for CNS Distribution - 27 Mar, 2024
Cipla has entered into multiple partnerships and agreements to expand its healthcare offerings. The company is evaluating acquisitions in various areas and aims to become an integrated healthcare player. It has a net cash balance of Rs 7,143 crore as of December 2023.
Cipla Announces Distribution Partnership with Sanofi India - 26 Mar, 2024
Cipla has entered into an exclusive distribution and marketing partnership with Sanofi India for the sale and promotion of its Central Nervous System (CNS) product line in India. Additionally, Cipla will transfer its generics business to its wholly-owned subsidiary, CPLS, for Rs 350 crore.
Cipla Ltd's Stock Up by 17% in Last Three Months - 22 Mar, 2024
Cipla Ltd's stock has seen a significant increase of 17% over the last three months. The company's key performance indicators, including ROE and earnings growth, have been positive, but industry analyst forecasts predict a slowdown in earnings growth.
Jan Aushadhi Scheme Dominates India's Rs 10,000-Crore Generics Market - 19 Mar, 2024
Cipla and Alkem are among the companies competing in India's small but growing generics market. However, the Jan Aushadhi scheme, a government initiative to provide affordable medicines, dominates the sector.
Fundamentals of Cipla Ltd
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 16.45% to 16.63% in Dec 2023 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 33.40% of holdings in Dec 2023 quarter
- NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 140.0% return, outperforming this stock by 94.7%
- NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 54.0% return, outperforming this stock by 2.3%
NEGATIVE IMPACTPrice Dip
In the last 1 month, CIPLA stock has moved down by -7.6%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 1.13K Cr → 1.05K Cr (in ₹), with an average decrease of 6.6% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 25.69% to 25.68% in Dec 2023 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 6.85K Cr → 6.78K Cr (in ₹), with an average decrease of 1.0% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 16.57% to 16.43% in Dec 2023 quarter
Cipla Ltd Valuation
Cipla Ltd in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (29.93x)
April 16, 2024
Industry (60.97x)
April 16, 2024
Highest (42.80x)
January 23, 2018
Mutual Fund Holdings
| Funds | Holdings |
 HDFC Flexi Cap Fund -Direct Plan - Growth Option | 5.59% |
 SBI Equity Hybrid Fund Direct Growth | 2.23% |
| HDFC ELSS TaxSaver -Direct Plan - Growth Option | 5.56% |
 Parag Parikh Flexi Cap Direct Growth | 1.03% |
 Kotak Flexicap Fund Direct Growth | 1.34% |
Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 33.4% | 0.00 | |
| Foreign Institutions | 25.68% | ||
| Mutual Funds | 16.63% | 1.11 | |
| Retail Investors | 16.43% | ||
| Others | 7.87% |
Technicals of Cipla Ltd share
News & Events of Cipla Ltd
News
Big movers on D-Street: What should investors do with Canara Bank, Paytm and PB Fintech?
Stocks that were in focus included names like Canara Bank, which jumped nearly 0.62%, Paytm, which fell 1.16%, and PB Fintech, whose shares rose 3.22% on Wednes... Read more
12 Apr, 2024 07:49 AMPaytm denies government withheld its plea to invest in payment services arm
Earlier this year, it was reported that the Centre was reportedly examining foreign direct investment (FDI) originating from China in Paytm Payments Services Lt... Read more
16 Apr, 2024 09:56 PMPaytm Starts User Migration To New UPI IDS And How It Will Affect You? Read Inside
OCL, Paytm's parent firm, has initiated the migration process of its customers to new payment service provider banks after the NPCI gave its nod for the same.
17 Apr, 2024 10:13 PMFrequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Cipla Ltd shares.
Cipla Ltd (CIPLA) share price today is ₹1375.2
Cipla Ltd is listed on NSE
Cipla Ltd is listed on BSE
- Today’s highest price of Cipla Ltd is ₹1391.95.
- Today’s lowest price of Cipla Ltd is ₹1371.55.
PE Ratio of Cipla Ltd is 29.93
PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share
Today’s traded volume of Cipla Ltd(CIPLA) is 14.34L.
Today’s market capitalisation of Cipla Ltd(CIPLA) is ₹111029.12Cr.
| Cipla Ltd(CIPLA | Price |
|---|---|
52 Week High | ₹1519 |
52 Week Low | ₹896.3 |
Cipla Ltd(CIPLA) share price is ₹1375.2. It is down -9.47% from its 52 Week High price of ₹1519
Cipla Ltd(CIPLA) share price is ₹1375.2. It is up 53.43% from its 52 Week Low price of ₹896.3
| Cipla Ltd(CIPLA | Returns |
|---|---|
1 Day Returns | -6.2% |
1 Month Returns | -7.61% |
3 Month Returns | 6.28% |
1 Year Returns | 51.71% |